Sesame Biopharmaceuticals Limited (hereinafter referred to as 'Sesame') was successfully listed on November 5, 2021. The global number of shares issued was 150,000,000 shares, with a subscription price of HK$13.38 per share, raising approximately HK$1.87 billion.
During the Hong Kong listing process, Frost & Sullivan mainly undertook the following tasks: helping the company accurately and objectively understand its positioning in the target market, using objective market data to discover, support, and highlight the company's competitive advantages, assisting the company, investment banks, and other intermediaries in completing relevant parts of the prospectus (such as the overview, competitive advantages and strategy, industry overview, business, and other important sections), facilitating communication with the Hong Kong Stock Exchange and investors, helping investors quickly understand the market ecosystem and competitive landscape, and assisting the company in completing feedback on various industry-related issues from the Hong Kong Stock Exchange, etc.
Trimer-Tag™(Protein Trimerization)
Overview of Patent Technology Platform
Trimer-Tag is the only technology platform in the world that uses human-derived trimerization tags to design and develop secreted covalently linked recombinant trimeric fusion proteins. Trimeric proteins developed using the Trimer-Tag technology platform are highly effective and safe against trimer-dependent disease targets. This technology platform enables the trimerization of target proteins, thereby targeting a wide range of natural diseases that rely on protein trimerization and biological targets, offering broad research and development potential. This includes dozens of enveloped RNA viruses such as coronaviruses, rabies virus, respiratory syncytial virus, influenza virus, human immunodeficiency virus, and Ebola virus, as well as cytokines from the tumor necrosis factor superfamily. These tumor necrosis factor superfamily cytokines have multiple important biological functions and are associated with certain cancers and autoimmune diseases. Therefore, for a variety of viruses and TNFSF-related diseases, the Trimer-Tag technology platform has considerable market potential in global disease areas.
"S-trimer" recombinant protein
Overview of the COVID-19 Candidate Vaccine SCB-2019
One of the core products of Clover is the 'S-trimer' recombinant protein COVID-19 candidate vaccine SCB-2019. Unlike traditional inactivated virus vaccines, Clover mainly uses Trimer-Tag technology and genetic recombination methods to construct an expression vector for the 'S-trimer' recombinant protein vaccine gene. Through gene transfection, a covalent trimer fusion protein recombinant antigen 'S-trimer' that is highly conformationally similar to the natural surface antigen S protein of coronaviruses is expressed and purified in mammalian cells. The vaccine has achieved primary and secondary endpoints for protective efficacy in global pivotal Phase 2/3 clinical trials, with an overall protective efficacy of 67% against any severe illness caused by any strain. The Delta variant is currently the main prevalent strain globally, accounting for more than 90% of all COVID-19 cases worldwide. All observed COVID-19 strains in the analysis of this clinical trial results were variants, showing that the protective efficacy of the COVID-19 candidate vaccine SCB-2019 against COVID-19 caused by the Delta variant was 79%, against the Gamma variant was 92%, and against the Mu variant was 59%.
Relying on its unique technical barriers in vaccine research and development, Clover has taken the lead in achieving a qualitative breakthrough in solving the problem of global COVID-19 variants. At the same time, Clover is the first innovative biopharmaceutical company on the Chinese mainland to receive CEPI funding and cooperation. CEPI has agreed to provide up to $3.605 billion in funding to support the development of SCB-2019. SCB-2019 is expected to become one of the first recombinant protein COVID-19 vaccines to be commercially launched globally, with a promising commercial outlook.
Protein tripeptide
Overview of Antitumor Targeted Drug SCB-313
SCB-313, as one of the Clover clinical pipeline products, is an innovative recombinant human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-trimer fusion protein used for the treatment of patients with malignant intracavitary tumors. Malignant intracavitary tumors include malignant ascites, malignant pleural effusion, and peritoneal cancer. These tumors have a large patient population, with an estimated global number of 3.03 million patients by 2030, and 760,000 in China. Malignant intracavitary tumors have always been considered a major clinical challenge by oncologists, severely affecting the quality of life and survival period of patients. Currently, there are no effective treatment methods in clinical practice, and there is a high unmet clinical need for many cancer patients worldwide.
Global and Chinese SCB-313 Competitive Landscape
Source: Frost & Sullivan report
Enbrel® (etanercept)
Overview of Biosimilar SCB-808
SCB-808 is a biosimilar of the pre-filled small-volume injection Enbrel®, used for the treatment of rheumatic diseases, including ankylosing spondylitis and rheumatoid arthritis. It is expected that by 2030, there will be 6.41 million people with rheumatoid arthritis and 4.05 million patients with ankylosing spondylitis in China. The treatment of ankylosing spondylitis and other rheumatic diseases remains an unmet medical need, with most patients still suffering from severe under-treatment. Clover Biologics has developed SCB-808 as a pre-filled small-volume injection that allows patients or their families to administer injections at home, filling the gap in the domestic market for enbrel aqueous injections.
Competitive landscape of Enbrel and similar drugs in China
Source: Frost & Sullivan report
Frost & Sullivan, integrating 60 years of global consulting experience, has dedicated 23 years to serving the booming Chinese market. With a global perspective, we help clients accelerate their business growth and achieve benchmark positions in industry growth, innovation, and leadership. The healthcare industry is one of the core areas of focus for Frost & Sullivan. Over the past sixteen years, the Frost & Sullivan healthcare team has provided financing financial advisory, IPO industry advisory, strategic consulting, management consulting, and other services to hundreds of outstanding domestic and international biopharmaceutical, medical device, healthcare services, and internet healthcare companies. Successful listings include: MicroPort Robotics (2252.HK), Huiyuan Kaiman (2256.HK), Kunbo Medical (2216.HK), Xianruida (6669.HK), Kangsheng Global (9960.HK), Yimaitong (2192.HK), Tengsheng Bopharm (2137.HK), Canoa (2162.HK), Chaoyu Ophthalmology (2219.HK), Guichuang Tongqiao (2190.HK), Huihuang Medicine (0013.HK), Koi Pharmaceutical (2171.HK), Zhaoke Ophthalmology (6622.HK), Nature Pharmaceuticals (UPC.NASDAQ), Sainov Biotech (6600.HK), Zhaoyan New Drugs (6127.HK), Novogene Health (6606.HK), Tianyan Pharmaceuticals (ADAG.NASDAQ), Beikang Medical (2170.HK), Jianbimiao Miao (2161.HK), MicroPort HeartLink (2160.HK), RuiLi Medical Beauty (2135.HK), Jiaosisi Pharmaceutical (1167.HK), HepoB (2142.HK), JD Health (6618.HK), Deqi Pharmaceutical (6996.HK), Rongchang Biotech (9995.HK), WuXi AppTec (2126.HK), SonoPharm (2096.HK), Yunding New Energy (1952.HK), Jiahe Biotech (6998.HK), ZaiDing Pharmaceutical (9688.HK), Ocular Therapeutics (1477.HK), Yongtai Biotech (6978.HK), Hapu Biopharmaceuticals (9989.HK), Kechuang Pharmaceutical (9939.HK), Peijia Medical (9996.HK), Kangfang Biotech (9926.HK), Novogene (9969.HK), Tianjing Biotech (IMAB.NASDAQ), Kanglong Chemical (3759.HK), China Antibody (3681.HK), Dongyao Pharmaceutical (1875.HK), Yasheng Pharmaceutical (6855.HK), Fuhong Hanlin (2696.HK), Hansoh Pharmaceutical (3692.HK), Mabtech (2181.HK), Fangda Holdings (1521.HK), Via Biotech (1873.HK), CStone Pharmaceuticals (2616.HK), Junshi Biosciences (1877.HK), WuXi AppTec (2359.HK), Innovent Biologics (1801.HK), Hailun Medicine (2552.HK), BeiGene (6160.HK), Gilead Sciences (1672.HK), WuXi Biotech (2269.HK), China Resources Pharmaceutical (3320.HK), Jacobus Pharmaceuticals (2633.HK), Huihuang China Medicine (HCM.NASDAQ), Kintsai Biotechnology (1548.HK), BBI Life Sciences (1035.HK), etc. In terms of the number of filings, the Frost & Sullivan healthcare team maintains an absolute leading position in Hong Kong's healthcare IPO market, continuously occupying more than 90% of the market share from 2018 to 2020.
Since the listing of the first batch of companies on the Sci-tech Innovation Board in July 2019, Frost & Sullivan reports have been widely cited in the prospectuses of leading Sci-tech Innovation Board-listed companies, including: Chengda Biology (688739.SH), Huaxi Biology (688363.SH), Junshi Biology (688180.SH), Zhejiang Genomics & Biotechnology Co., Ltd. (688266.SH), Beiogen Pharmaceutical (688177.SH), and Shenzhou Cells (688520.SH). They are considered the most powerful, professional, and influential industry research institutions in the sector. We hope to work with enterprises to understand industry trends, seize development opportunities, jointly promote innovation and upgrading of China's health industry, and build a healthy future.
Recommended Reading
Frost & Sullivan helps RuiLi Medical Beauty successfully go public in Hong Kong (2135.HK)
24. Frost & Sullivan helps JD Health successfully list on the Hong Kong Stock Exchange (6618.HK)
39. Frost & Sullivan assisted Tianjing Biology in successfully going public in the US (IMAB.NASDAQ)
51. Frost & Sullivan helps WuXi AppTec successfully list on the Hong Kong Stock Exchange (2359.HK)
